Category Archives: Uncategorized

Pumping the brakes on med tech optimism … or not

There’s more to med tech than just money, but it’s pretty tough to do much without it. Consequently, money is topical, but one expert sees a more difficult road ahead than anticipated for investors in digital health, while another says…

FacebookTwitterGoogle+Share

ACC 2018: Data for Heartmate 3 suggest a study against transplants

By Mark McCarty, Regulatory Editor Some devices are just the latest and best in class while others force clinicians to revisit long-held assumptions about the possibilities of a device type. This appears to be the case with an interim report…

FacebookTwitterGoogle+Share

ACC 2018: Five-year Corevalve data closely track SAVR outcomes

By Mark McCarty, Regulatory Editor Five-year data for novel cardiology devices are often unavailable before that iteration of the device has become obsolete, but those data are nonetheless important. Hans Gustav Thyregod of Copenhagen University Hospital reported five-year data for…

FacebookTwitterGoogle+Share

ACC 2018: ICD vest associated with lower all-cause death, but not SCD

ORLANDO, Fla. − It’s always difficult to explain why a device therapy reduces overall mortality without affecting mortality for the condition under treatment, but that’s the dilemma facing the trialists involved in the study of a lightweight defibrillator vest that…

FacebookTwitterGoogle+Share

Carryover; Two 2017 Stories for 2018

2017 was quite the year in terms of device regulations, but payers had an interesting time of it as well. Following are a couple of developments that promise to carry over into the new year, with unpredictable consequences. Tapping the…

FacebookTwitterGoogle+Share

Small Changes; FDA and the 510(k)

Tom Waits once sang of a character named Small Change, who apparently “got rained on with his own .38,” and device makers might sometimes have felt as though small changes to their devices didn’t always work out so well, either….

FacebookTwitterGoogle+Share

Accelerated; Language and the New FDA

We’ve all been witness to a variety of predicaments in terms of the FDA’s premarket review of biologics, drugs and devices, but while controversies abound, there’s also this nagging question of how words color perception. It’s an important consideration, one…

FacebookTwitterGoogle+Share

Closing the Absorb chapter

Two years ago, my youngest child was just learning how to walk and analysts were praising Abbott Laboratories’ bioresorbable vascular scaffold. Flash forward today – my son is riding his bike like a true champ (with training wheels) and Abbott is …

FacebookTwitterGoogle+Share

Tempest Fugit; The 2017 MedTech Conference

This year’s med tech conference was a lot like previous years’ events, but the heat of the moment is always telling, isn’t it? Following are a few developments that were part of the conference by design or by chance, but…

FacebookTwitterGoogle+Share

Is open source the future of pharma and med tech, or an anomaly?

Technology seems to leap ahead at an astounding pace and is disruptive for many businesses, but is achingly slow for patients who await disease detection and treatments. A recent TED Radio Hour, “Fighting Cancer,” included speakers who addressed their approaches…

FacebookTwitterGoogle+Share

Marketo